Alzheimer's disease: experimental models and reality

Area of Science:

• Neuroscience
• Pathology
• Pharmacology

Background:

• Alzheimer's disease (AD) research relies heavily on experimental models to understand pathogenesis and test therapies.
• Current models, primarily transgenic mice overexpressing familial AD (FAD) genes, often replicate only amyloid plaque pathology, not the full spectrum of AD, including neurofibrillary tangles.
• The high failure rate in AD clinical trials is partly attributed to the oversimplified nature of preclinical models.

Purpose of the Study:

• To critically review the pathological features and limitations of major experimental models used in Alzheimer's disease research.
• To provide insights that can enhance the successful translation of therapeutic strategies from preclinical studies to human patients.
• To guide researchers in selecting appropriate models for evaluating novel therapeutic approaches.

Main Methods:

• Review of existing literature on experimental models of Alzheimer's disease.
• Analysis of pathological characteristics and limitations of various animal models (transgenic mice, transgenic rats).
• Evaluation of physiological models for sporadic AD and in vitro human cell culture systems.

Main Results:

• Transgenic mouse models commonly used for AD research exhibit amyloid plaque formation but often lack neurofibrillary tangle pathology.
• Existing models present a limited view of AD, contributing to the poor success rate of clinical trials.
• A comprehensive understanding of model strengths and weaknesses is necessary for effective therapeutic evaluation.

Conclusions:

• No single experimental model fully recapitulates Alzheimer's disease complexity.
• Utilizing multiple models with diverse strengths and weaknesses is essential for robust preclinical testing.
• Improved model selection and validation are critical to increasing the success rate of AD therapies in clinical trials.